IRIS UniCatt

Baldin, Gianmaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 947
AS - Asia 754
EU - Europa 581
SA - Sud America 227
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.536
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 903
SG - Singapore 339
CN - Cina 221
BR - Brasile 188
SE - Svezia 145
IT - Italia 111
DE - Germania 87
FR - Francia 82
IN - India 48
VN - Vietnam 42
FI - Finlandia 28
ID - Indonesia 28
IE - Irlanda 28
GB - Regno Unito 26
CA - Canada 25
AR - Argentina 19
PL - Polonia 15
RU - Federazione Russa 14
MX - Messico 12
KR - Corea 11
AT - Austria 10
BD - Bangladesh 10
JP - Giappone 10
TR - Turchia 10
HK - Hong Kong 9
ZA - Sudafrica 9
EC - Ecuador 7
UA - Ucraina 7
BE - Belgio 6
CO - Colombia 6
ES - Italia 6
KE - Kenya 5
LT - Lituania 4
AE - Emirati Arabi Uniti 3
IQ - Iraq 3
TT - Trinidad e Tobago 3
CH - Svizzera 2
CI - Costa d'Avorio 2
CL - Cile 2
DZ - Algeria 2
IR - Iran 2
LV - Lettonia 2
NL - Olanda 2
NO - Norvegia 2
OM - Oman 2
PE - Perù 2
TN - Tunisia 2
TW - Taiwan 2
UZ - Uzbekistan 2
VE - Venezuela 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
JO - Giordania 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SN - Senegal 1
TG - Togo 1
TH - Thailandia 1
Totale 2.536
Salva come PNG Salva come JPEG
Città #
Chandler 189
Singapore 168
Ashburn 106
New York 60
Beijing 37
Hefei 36
Rome 29
Dublin 28
Redmond 25
San Mateo 25
Los Angeles 24
Jakarta 23
Nanjing 22
Boston 21
Milan 21
São Paulo 21
Munich 18
Ho Chi Minh City 17
Cattolica 16
Dearborn 15
Frankfurt am Main 15
Princeton 15
Redwood City 15
Helsinki 14
The Dalles 14
Wilmington 14
Montreal 11
Brooklyn 10
Jacksonville 10
Kent 10
Marseille 10
Seoul 10
Tokyo 10
Turku 9
Hong Kong 8
Toronto 8
Bexley 7
Changsha 7
Guangzhou 7
Hanoi 7
Vienna 7
Warsaw 7
Belo Horizonte 6
Brussels 6
Chicago 6
Denver 6
Moscow 6
Mumbai 6
Santa Clara 6
Shenyang 6
Tianjin 6
Buffalo 5
London 5
Mexico City 5
Washington 5
Buenos Aires 4
Chennai 4
Düsseldorf 4
Houston 4
Jiaxing 4
Johannesburg 4
Kraków 4
Lauterbourg 4
Nanchang 4
Orem 4
Querétaro 4
Stockholm 4
Alcalá de Henares 3
Atlanta 3
Augusta 3
Biên Hòa 3
Brasília 3
Campinas 3
Fairfield 3
Guarulhos 3
Jinan 3
Lawrence 3
Mountain View 3
New Delhi 3
Nuremberg 3
Ottawa 3
Phoenix 3
Poplar 3
Portland 3
Quito 3
Ribeirão Preto 3
Rio de Janeiro 3
Roubaix 3
Seattle 3
Shanghai 3
Abidjan 2
Ankara 2
Ann Arbor 2
Belém 2
Cape Town 2
Catanduva 2
Chengdu 2
Chongqing 2
Cincinnati 2
Corrientes 2
Totale 1.337
Salva come PNG Salva come JPEG
Nome #
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 136
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 124
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 123
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 122
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 117
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 115
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 111
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 111
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 107
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 103
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 102
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 100
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 94
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 92
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 90
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 87
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 86
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 85
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 81
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 81
Predictors of choice of initial antifungal treatment in intraabdominal candidiasis 79
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 71
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 69
Necrotizing mpox with persistent microbiological positivity despite the use of tecovirimat: A case report 68
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice 64
Autochthonous dengue outbreak in Rome, Italy, in 2023 62
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV 57
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 45
Totale 2.582
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.403
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.403
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202148 0 0 0 0 0 5 2 1 4 13 17 6
2021/2022155 4 0 4 24 5 6 0 27 3 15 25 42
2022/2023438 63 65 38 61 24 46 25 40 54 1 11 10
2023/2024221 13 40 4 20 4 79 6 6 1 8 21 19
2024/2025562 13 8 46 28 46 28 45 19 46 41 137 105
2025/2026844 191 52 93 216 252 40 0 0 0 0 0 0
Totale 2.582